News

The company describes KSI-101 as a “novel, potent, and high-strength (100 mg/mL) antibody-based investigational therapy with a bispecific mechanism of action targeting both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF).”

OPGx-LCA5 is designed to address a form of Leber congenital amaurosis that results from biallelic mutations in the LCA5 gene, which encodes the lebercilin protein, the investigators explained.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform treatment and improve children's vision.

The trial is evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

Host Deborah Ristvedt, DO, is joined by Marguerite B. McDonald, MD, FACS, to discuss her journey with pioneering contributions to ophthalmology, patient-centered care, leadership, and guidance for the next generation.

Johnson & Johnson reaches 100,000 TECNIS ODYSSEY IOLs implanted, and presented data on in vision correction and patient satisfaction at the AAO 2025 meeting.

The VITA Trial is a prospective pilot study on the VisiPlate Aqueous Shunt in patients with with open-angle glaucoma.

The trial met both its primary efficacy and key secondary endpoints.

The EXTEND study is a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial.

The trial will be evaluating AXPAXLI dosed every 6 months versus aflibercept (2 mg) dosed every 8 weeks in treatment-naïve wet AMD patients.

Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets.

The funding will support the completion of the clinical PoC of its AAVB-039 CELESTE study and the completion of the STELLA natural history study

Veligrotug is an intravenously delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody for the treatment of thyroid eye disease (TED).

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

Marguerite B. McDonald, MD, FACS, reflects on a first-year residency case that taught her the importance of trusting her instincts and advocating for patient safety.

Dr. James Chelnis explores innovative energy-based technologies in aesthetic facial surgery, emphasizing safety, personalized treatments, and future advancements in patient care.

Ophthalmologists discuss topography-guided techniques, long-term corneal health, and emerging technologies set to transform refractive surgery.

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young patients.

Deborah A. Ferrington, PhD, highlights how breakthroughs in imaging, AI, and stem cell research are reshaping ophthalmology.

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient awareness and surgical presence.

Emerging devices, wearable technology, and home-monitoring tools are reshaping how clinicians diagnose, treat, and manage patients.

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD.

The results presented at 2025 European Society of Medical Oncology meeting support neoadjuvant darovasertib as a potential treatment to delay or prevent progression of the disease.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.